Jane Street
ATNM icon

Jane Street’s Actinium Pharmaceuticals ATNM Stock Holding History

Jane Street’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.1K Sell
19,500
-6,900
-26% -$7.97K ﹤0.01% 11220
2026
Q1 		$26.3K Sell
26,400
-3,300
-11% -$3.92K ﹤0.01% 11141
2025
Q4 		$40.4K Buy
+29,700
New +$43.3K ﹤0.01% 10565
2023
Q1 		– Sell
-37,600
Closed -$400K – 8989
2022
Q4 		$400K Buy
+37,600
New +$382K ﹤0.01% 6524

Other funds holding ATNM

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Compass Financial Management Tampa, Florida $829M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street's ATNM Position: Q2 2026 in Review

Jane Street sold out of Actinium Pharmaceuticals (ATNM) in Q2 2026, closing a stake of 34,299 shares — an estimated $39.6K sold.

Jane Street first reported a position in ATNM in Q2 2015 and held it in 14 quarters. The position peaked at $1.17M in Q1 2023. 47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

  • Jane Street reported no remaining Actinium Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 34,299 Actinium Pharmaceuticals shares in Q2 2026, an estimated $39.6K.
  • Jane Street first reported a position in Actinium Pharmaceuticals in Q2 2015 and held it in 14 quarters.
  • Jane Street's Actinium Pharmaceuticals position peaked at $1.17M in Q1 2023.
  • 47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.